Blog
RSS FeedPosted by Michael Wonder on 09 Feb 2022
Evolus receives acceptance of submission in Australia, a pivotal step in approval process for Nuceiva
8 February 2022 - Evolus today announced the acceptance of its submission to the Australian TGA for regulatory approval of Nuceiva ...
Posted by Michael Wonder on 08 Feb 2022
Three million Novavax doses touch down in Australia ahead of final TGA approval
8 February 2022 - Millions of Novavax vaccinations have arrived in Australia giving the country a new weapon against COVID-19. ...
Posted by Michael Wonder on 05 Feb 2022
TGA approves provisional determination for Gilead for COVID-19 treatment, Veklury (remdesivir), for proposed use in children and adults who are at risk of progressing to severe COVID-19
5 February 2022 - The TGA has granted a second provisional determination to Gilead in relation to its COVID-19 treatment, ...
Posted by Michael Wonder on 04 Feb 2022
To hell and back: devices meant to ease pain are causing trauma
5 February 2022 - A $35,000 treatment at the forefront of medical technology which pumps electric pulses into the spine ...
Posted by Michael Wonder on 03 Feb 2022
COVID-19 vaccine weekly safety report (3 February 2022)
3 January 2022 - To 30 January 2022, the TGA has received 440 reports which have been assessed as likely ...
Posted by Michael Wonder on 02 Feb 2022
ATAGI recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years
3 January 2022 - The Australian Technical Advisory Group on Immunisation (ATAGI) has made recommendations for use of Pfizer COVID-19 vaccine ...
Posted by Michael Wonder on 31 Jan 2022
ATAGI update following weekly COVID-19 meeting (27 January 2022)
31 January 2022 - On Thursday 27 January 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 28 Jan 2022
Pfizer's COVID-19 vaccine (Comirnaty) provisionally approved for use as a booster in individuals aged 16-17 years old
28 January 2022 - The Therapeutic Goods Administration has provisionally approved the Pfizer COVID-19 vaccine, Comirnaty for use as a ...
Posted by Michael Wonder on 27 Jan 2022
Moderna aims to deliver Omicron COVID-19 vaccine by September
27 January 2022 - A COVID-19 booster shot, targeted specifically at the Omicron variant, is expected to be delivered by ...
Posted by Michael Wonder on 27 Jan 2022
TGA approves Tepmetko for patients with non-small-cell lung cancer
27 January 2022 - Tepotinib (Tepmetko) has provisional approval in Australia for the treatment of adult patients with locally advanced or ...
Posted by Michael Wonder on 27 Jan 2022
COVID-19 vaccine weekly safety report (27 January 2022)
27 January 2022 - To 23 January 2022, the TGA has received 431 reports which have been assessed as likely to ...
Posted by Michael Wonder on 24 Jan 2022
TGA approves MSD's Vaxneuvance
24 January 2022 - Vaxneuvance (pneumococcal 15 valent conjugate vaccine (CRM197 protein)) was approved on 17 January 2022 for active ...
Posted by Michael Wonder on 23 Jan 2022
ATAGI statement on the use of Novavax COVID-19 vaccine (Nuvaxovid)
24 January 2022 - ATAGI recommends that Novavax COVID-19 vaccine can be used for the primary course of COVID-19 vaccination ...
Posted by Michael Wonder on 20 Jan 2022
COVID-19 vaccine weekly safety report (20 January 2022)
20 January 2022 - To 16 January 2022, the TGA has received 428 reports which have been assessed as likely to ...
Posted by Michael Wonder on 20 Jan 2022
Statement on the arrival of the Novavax vaccine and COVID-19 pills
20 January 2022 - Medicines Australia welcomes the TGA’s provisional approval for the Novavax COVID-19 vaccine and the provisional approval ...